Please login to the form below

Not currently logged in
Email:
Password:

AVEO's financial head joins ImmunoGen

David Johnston appointed chief financial officer
David Johnston, Immunogen

David Johnston has left his role as chief financial officer of AVEO Pharmaceuticals to join ImmunoGen in the same role.

Johnston's switch comes after more than six years at AVEO having joined the company from his role as senior VP of finance corporate planning and analysis at Genzyme.

Other previous roles include VP finance and chief financial officer of Genzyme Biosurgery.

In his new role, Johnston will head the financial operations of one of the leading biotechs working to develop antibody-drug conjugates in cancer, with ImmunoGen's successes including the breast cancer treatment Kadcyla (trastuzumab emtansin) it developed in partnership with Roche.

“I am delighted to have Dave join ImmunoGen,” commented ImmunoGen's CEO Daniel Junius.

“His depth of experience in both senior financial positions and in corporate planning makes Dave well-suited to help successfully advance the company to our next stages,” added Junius.

7th January 2014

From: Research, Sales

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
Sharing patient stories for World Pulmonary Hypertension Day
For World Pulmonary Hypertension Day and we’re here to help raise awareness of pulmonary hypertension (PH) - a frequently under and misdiagnosed condition. Created in collaboration with the PH patient...